Although evidence have clearly proved that intravitreal injection of vascular endothelial
growth factor antagonists prevents vision loss and may even improve visual acuity in patients
with neovascular AMD, a significant percentage of patients continue to lose visual acuity.
Moreover, monthly intravitreal injections represent a burden for society as well as the
caregiver.
Combination therapy with either topical 0.1% pranoprofen or nutraceutical support with AREDS2
formula plus omega-3 might act synergistically with intravitreal injection, offering valuable
therapeutic support to aflibercept injections in patients requiring long-term treatment.